Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Alitair Pharmaceuticals has retained Finn, Warnke & Gayton to sell two Alitair patents and an associated royalty stream at a sealed bid sale on 24 May 2013.
Subscribe to our email newsletter
The first patent, which was issued in 2012, covers the use of ion exchange resins in immediate-release and extended-release oral dosage forms.
Issued in 2013, the second patent covers the use of ion exchange resins in immediate-release and extended-release oral formulations of benzonatate, a non-narcotic prescription cough product.
The royalty stream includes milestone payments and has an estimated net present value of $7.5m.
Either of the patents or both along with the royalty stream will be sold at the sealed bid sale, according to Alitair.